The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.įate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that are designed to be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. In the United States, it accounts for around 25,000 deaths a year, and experts say that in Britain liver disease death rates among young and middle-aged people are increasing at a rate of 8 to 10 percent a year.Preclinical in vivo model development: Highlighting success and discussing xenograft advancements, a step closer in predicting patient outcomesĪbout Fate Therapeutics’ iPSC Product Platform Liver disease is the fifth largest cause of death in developed nations after cardiovascular, cancer, stroke, and respiratory diseases. “The cells we created were just as good as if we had used embryonic stem cells.”Įmbryonic stem cells are seen as the most powerful and malleable type of cells but are controversial because they are harvested from human embryos when they are just a few days old. “This technology bypasses the need for using human embryos,” said Tamir Rashid of Cambridge’s laboratory for regenerative medicine, who led the study. REUTERS/Julie Baker/Stanford University School of Medicine/California Institute for Regenerative Medicine/HandoutĬambridge University scientists who reported their results in the Journal of Clinical Investigation on Wednesday, said they also found a way of avoiding the kind of intense political and ethical rows over embryonic stem cells which are currently hampering work in the United States. A microsopic view shows human embryonic stem cells in various stages of differentiation into liver cells in this photo taken at Stanford University and released by the California Institute for Regenerative Medicine, March 9, 2009.

Induced pluripotent stem cells